TOM1L1

Across TCGA pan-cancer cohorts, TOM1L1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TOM1L1 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TOM1L1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TOM1L1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where TOM1L1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	III,IV	0.857	0.454	.014	25	view →
PDAC	DFS	Tertile	All	0.554	0.364	.009	19	view →
UCEC	DFS	Median	II,III,IV	0.875	0.532	.024	18	view →
HNSC	DFS	Median	II,III,IV	0.777	0.544	.008	13	view →
LSCC	OS	Tertile	III,IV	0.451	0.853	.038	3	view →
LUAD	OS	Median	III,IV	0.609	0.226	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TOM1L1–CCRCC (OS)

Open the CCRCC breakdown →